Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: iStock
The World Health Organization today declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a “public health emergency of international concern” (PHEIC), citing the risk of spread to neighboring countries.
The WHO defines a Public Health Emergency as an extraordinary event or crisis that poses a substantial risk of widespread illness, injury, or death to a population, such as pandemics, severe pollution events, or natural disasters.
However, the WHO clarified that the outbreak, caused by the Bundibugyo virus, does not meet the criteria for a pandemic emergency. Countries sharing land borders with the DRC were described as being at high risk for further spread.
“The Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of pandemic emergency, as defined in the International Health Regulations (2005) (IHR),” the WHO said in a statement.
Ebola Outbreak: Cases And Deaths
The UN health agency said the outbreak has caused 80 deaths, with eight laboratory-confirmed cases and 246 suspected Ebola cases reported in Ituri Province in the DR Congo, across Bunia, Rwampara, and Mongbwalu.
In addition, two laboratory-confirmed cases — including one death — with no apparent link to each other were reported in Kampala, Uganda, within 24 hours of each other, indicating international spread. Both individuals had travelled separately from the DR Congo.
A laboratory-confirmed case has also been reported in Kinshasa, DR Congo, involving a person returning from Ituri.
The WHO further noted unusual clusters of community deaths and said the outbreak poses a public health risk to other countries through international spread, which has already been documented.
What Is Bundibugyo Virus Disease?
Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past. It is different from other known ebolaviruses such as the Zaire ebolavirus and Sudan ebolavirus.
The virus was first identified during an outbreak in 2007, which resulted in more than 100 cases before being declared over in early 2008.
The WHO described the current outbreak as “extraordinary” because there are no approved Bundibugyo virus-specific therapeutics or vaccines, unlike the Ebola-Zaire strain. Most of the country’s previous outbreaks were caused by the Zaire strain.
According to US Centers for Disease Control and Prevention (CDC), the Bundibugyo strain spreads through contact with the blood or body fluids of infected individuals or people who have died from the disease.
Transmission can also occur through contact with contaminated objects such as clothing, bedding, needles, and medical equipment, or through infected animals including bats and nonhuman primates.
Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising in the later stages of illness.
Read More: Can Hantavirus Spread Through Semen And Breast Milk? What Experts Say
The WHO advised immediate isolation of confirmed cases and daily monitoring of contacts. It also recommended restricting national travel for exposed individuals and avoiding international travel until 21 days after exposure.
At the same time, the agency urged countries not to close borders or restrict travel and trade out of fear, warning that such measures could lead to unmonitored informal border crossings.
Credit: iStock
Health officials at the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being caused by the rare Bundibugyo strain.
Bundibugyo ebolavirus was first isolated during an outbreak of hemorrhagic fever in Uganda in 2007. There are no vaccines or specific treatments approved to prevent or treat the Bundibugyo strain.
Preliminary laboratory results from the Institut National de Recherche Biomedicale (INRB) detected Ebola virus in 13 of 20 samples tested with the Bundibugyo Virus.
"Africa CDC is actively collaborating with health authorities in DRC, Uganda, and regional partners to deliver a coordinated response to confirmed Ebola Virus Disease cases linked to the Bundibugyo strain," the Africa CDC said in a statement.
"Rapid laboratory testing, contact tracing, cross-border surveillance, and enhanced infection prevention measures are already deployed to protect communities and stop the spread," it added.
As of the latest update from DRC, approximately 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones.
Four deaths have been reported among laboratory-confirmed cases.
Suspected cases have also been reported in Bunia and are pending confirmation. These figures remain provisional and are being validated through laboratory confirmation, line-list harmonization, contact identification, and epidemiological investigation.
Also read: Ebola Resurfaces In Eastern DR Congo In 17th Outbreak, Claims 65 Lives: All You Need To Know
Uganda’s Ministry of Health, in a statement, reported a confirmed Ebola Bundibugyo Virus Disease case in a 59-year-old Congolese male who was admitted to Kibuli Muslim Hospital on May 11 and died on May 14.
The country's officials reported the case as imported from DRC and have indicated that no local case has yet been confirmed.
Africa CDC noted that it remains concerned by the urban context of Bunia and Rwampara, with intense population movement, insecurity, mining-related mobility in Mongwalu, gaps in contact listing, infection prevention and control challenges, and the proximity of affected areas to Uganda and South Sudan.
Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past.
It is also spread by contact with contaminated objects (such as clothing, bedding, needles, and medical equipment), or by contact with animals, such as bats and nonhuman primates, that are infected with BVD.
Symptoms include fever, headache, muscle pain, weakness, diarrhea, vomiting, stomach pain, and unexplained bleeding or bruising (a late stage of illness).
Read More: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026
The US CDC advised people to avoid:
In case of infection, the CDC advises:
Credit: AI generated image
Even as the world is still grappling with the news of a hantavirus and two separate norovirus outbreaks, the Africa Centres for Disease Control and Prevention (Africa CDC) today confirmed that the Ebola virus has resurfaced in eastern Democratic Republic of the Congo for the 17th time.
In a statement, the Africa CDC reported that there are 246 suspected cases and 65 deaths, mainly in the mining areas of Mongwalu and Rwampara, about 100 kilometers north of the provincial capital, Bunia.
While tests are being carried out to identify the strain of the virus, early indications suggest the strain is not the Zaire variant, which has been responsible for several previous outbreaks in the country, the health officials said.
The Ebola Zaire strain was prominent in Congo’s past outbreaks, including the 2018 to 2020 outbreak in the eastern region that killed more than 1,000 people.
Ebola was first discovered in 1976 in the DR Congo. This is the 17th outbreak of the deadly viral disease in the country.
As per preliminary tests conducted at the Institut National de Recherche Biomédicale (INRB) in the country's capital, Kinshasa, the Ebola virus has been detected in 13 of 20 samples analysed, following consultations with DR Congo's Ministry of Health and National Public Institute.
Of the 65 deaths, four were reported among lab-confirmed cases, Africa CDC said.
Additional suspected cases have also been reported in Ituri's provincial capital, Bunia, a densely populated urban centre near the borders with Uganda and South Sudan, raising fears of regional transmission.
All affected communities and at-risk areas have been advised to follow guidelines from the national health authorities.
Also read: More Americans Exposed To Hantavirus; 41 Under Monitoring, Says CDC
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal.
People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person, such as saliva, urine, feces, or semen, or things that have body fluids of an infected person, like clothes or sheets.
Read More: Another Norovirus Outbreak Confirmed Aboard Cruise Ship In France; Over 1,700 People Trapped
Ebola enters the body through cuts in the skin or when one touches their eyes, nose, or mouth. Early symptoms include fever, fatigue, and headache.
It is a highly infectious and transmissible disease; in fact, there have been cases of healthcare workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducting burial ceremonies, involving direct contact with the body of the deceased, can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk or in pregnancy-related fluids and tissues.
Symptoms include:
According to the WHO, there are two vaccines against the Ebola virus. But both the Merck-developed Ervebo vaccine, administered in one dose, and Johnson & Johnson-developed Zabdeno and Mvabea vaccine, administered in a two-dose regimen, target Zaire ebolavirus.
The Ervebo vaccine is recommended for use in outbreak settings and is currently the only vaccine available in the global stockpile.
© 2024 Bennett, Coleman & Company Limited